Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07208305

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting in Adults with Advanced Cancer

Led by Affiliated Hospital of Qinghai University · Updated on 2026-04-27

222

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This trial studies adult patients with advanced cancer who are starting strong opioid therapy. It evaluates whether combined treatment with olanzapine and metoclopramide can prevent nausea and vomiting caused by opioids. The study also monitors adverse events to understand the safety of this combination compared to no preventive treatment. Participants are randomly assigned to either receive olanzapine (2.5 mg once nightly) plus metoclopramide (10 mg three times daily) for seven days or no preventive treatment. Both groups may receive other treatments if nausea or vomiting occur. The trial lasts one week with a group receiving medication and a control group without preventive drugs. During the study, researchers track nausea, vomiting, time to first symptoms, duration of symptoms, opioid use, adverse events, pain levels using the Numeric Rating Scale, and quality of life with the EQ-5D-5L questionnaire. The main outcome is the percentage of patients with complete control of nausea and vomiting over seven days. Safety and survival rates are also followed up to half a year.

CONDITIONS

Brief Title

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with malignant tumors confirmed by pathology or histology
  • Diagnosed with locally advanced or advanced cancer stages by imaging
  • Age 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
  • Expected to survive at least 4 weeks
  • Moderate or severe cancer pain with a Numeric Rating Scale (NRS) score of 4 or higher
  • Able to take oral medication
  • Starting treatment with strong opioid painkillers such as morphine, oxycodone, or fentanyl
  • No chemotherapy or radiotherapy within one month prior to enrollment
  • No nausea, vomiting, or intestinal obstruction at the time of enrollment
  • Capable of understanding and completing research evaluations and procedures
Not Eligible

You will not qualify if you...

  • Poorly controlled diabetes with clear diagnosis
  • Currently experiencing nausea or vomiting symptoms
  • Symptomatic brain diseases such as brain metastases or leptomeningeal metastasis
  • Chemotherapy within one week before or during the trial
  • Radiotherapy to head, abdomen, or pelvis within one week before or during the trial
  • Use of drugs with emetic or antiemetic effects within 48 hours before trial start
  • Severe electrolyte imbalance or abnormal kidney or liver function
  • Gastrointestinal bleeding
  • Pregnant or breastfeeding women
  • Diagnosed with breast cancer
  • Heart disease or prolonged QTc interval on electrocardiogram
  • Known allergy or contraindication to olanzapine or metoclopramide

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 7 days

Participants receive oral olanzapine once daily at night plus oral metoclopramide three times daily for 7 consecutive days to prevent opioid-induced nausea and vomiting. Participants in the control group do not receive preventive treatment.

Daily oral medication for 7 days

Follow-up

Duration - 7 days

Participants are monitored for adherence to opioid therapy and assessed for symptoms and side effects for an additional week after treatment ends.

Follow-up assessments during days 8 to 14

Trial Site Locations

Total: 1 location

1

Qinghai University Affiliated Hospital

Xining, Qinghai, China, 810000

Actively Recruiting

Loading map...

Research Team

J

Jiuda Zhao, Doctor

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Alternate Nostril Breathing (ANB) for 1st Trimester Nausea a...

Pregnancy Emesis

Actively Recruiting

1 location

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

Nausea and Vomiting

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here